Recent developments include quarterly financial results showing revenue growth with net losses, regulatory approvals for NanoKnife studies, and expansion of product indications and geographic reach.

• AngioDynamics reported a Q4 loss but revenue growth, with net sales increasing and continued investment in Med Tech products including Auryon and NanoKnife [N1].
• The company gained FDA IDE approval for a NanoKnife feasibility study in benign prostate hyperplasia, supporting clinical development [N2].
• NanoKnife system received BSI approval for CE mark in Europe, expanding indications for tumor ablation including prostate cancer [N2].
• Q3 earnings showed revenue growth with gross margin decline; Med Tech segment grew 19.0% while Med Device grew 1.2% [N4][N5].
• The company continues to expand NanoKnife applications in Europe for multi-organ tumor ablation [N2].

AngioDynamics demonstrates growth in its Med Tech segment driven by innovative products like Auryon, thrombus management systems, and the NanoKnife platform, which has received expanded regulatory clearances including FDA 510(k) and CE marks. The company’s diversified portfolio addresses multiple clinical needs in cardiovascular and oncology markets. Its direct sales model in the US and distributor network internationally support market penetration. Recent revenue growth and gross margin improvements reflect operational progress. The company’s focus on R&D and clinical pathway expansion may support continued product enhancements and new indications. Recent FDA IDE approval for NanoKnife BPH feasibility study and expansion in Europe indicate ongoing clinical development and geographic expansion [S1][S2][N2].

AngioDynamics reported net losses in recent periods, with a net loss of $36.7 million for fiscal year 2026 and ongoing quarterly losses, reflecting challenges in achieving profitability. The Med Device segment shows slower growth and some softness in Ports and Oncology product lines. The company faces pricing pressures due to managed care dynamics, healthcare provider consolidation, and competition from larger diversified medical device companies. Macroeconomic factors such as inflation, supply chain disruptions, labor shortages, and tariffs have impacted costs and margins. The company has divested certain business lines and discontinued some product lines, which may affect revenue diversification. Execution risks include regulatory approvals, integration of acquisitions, and market acceptance of new products. Liquidity is adequate but cash used in operations remains significant [S1][S2].

AngioDynamics' moat is supported by its diversified product portfolio across cardiovascular and oncology treatment devices, including proprietary technologies such as the NanoKnife IRE Ablation System and the Auryon Atherectomy System. The company benefits from FDA clearances and CE marks for multiple products, enabling expanded clinical indications and geographic reach. Its direct sales force in the US and established distributor relationships internationally provide market access. The integration of acquired technologies and ongoing R&D investments contribute to product innovation and differentiation. Additionally, proprietary features such as Endexo Technology in catheters and Vortex port technology enhance product performance and physician preference. However, the company operates in a competitive environment with large diversified medical device companies and faces pricing pressures from managed care and healthcare provider consolidation [S1][S2].

• Regulatory and Clinical Risks: The company’s products require FDA and other regulatory approvals; delays or failures in obtaining or maintaining these approvals could adversely affect operations. Clinical trial outcomes and regulatory pathway expansions are uncertain.
• Competitive Pressure and Pricing: AngioDynamics operates in a competitive market with large diversified medical device companies and smaller specialized firms. Pricing pressures from managed care and healthcare provider consolidation may impact margins and sales.
• Macroeconomic and Supply Chain Risks: Inflation, tariffs, labor shortages, and supply chain disruptions have increased costs and may continue to affect manufacturing and delivery of products.
• Profitability and Financial Performance: The company has reported net losses and negative earnings per share, with ongoing cash use in operations. Achieving sustained profitability remains a challenge.
• Integration and Execution Risks: Risks related to integrating acquisitions, divesting business lines, and successfully launching new products and expanding indications could impact growth and financial results.

• AngioDynamics is a diversified medical technology company focused on products and technologies for treatment of cardiovascular disease and cancer, with a strategy based on innovative R&D, clinical and regulatory pathway expansion, and customer-centric sales performance [S1].
• Founded in 1988 and headquartered in Latham, NY, with manufacturing primarily in Queensbury, NY [S1].
• The company has grown through acquisitions adding product lines including ablation and NanoKnife systems, vascular access products, angiographic products, dialysis, drainage, thrombolytic, embolization, and venous products [S1].
• Recent divestitures include dialysis and BioSentry businesses sold in 2023, and PICC and Midline businesses sold in 2024; discontinued RadioFrequency Ablation and Syntrax product lines as of February 2024 [S1].
• Product offerings are organized into two segments: Med Tech and Med Device, all FDA cleared for sale in the US [S1].
• Med Tech products include Auryon Atherectomy System for peripheral arterial disease, thrombus management portfolio (AlphaVac, AngioVac, Uni-Fuse catheters), and NanoKnife IRE Ablation System for soft tissue ablation using non-thermal electrical pulses [S1].
• NanoKnife received expanded FDA 510(k) clearance for prostate tissue ablation in December 2024 and BSI approval for CE mark in February 2026 for pancreas, kidney, liver, and prostate tumors [S1].
• Med Device products include peripheral products such as angiographic catheters, guidewires, drainage catheters, micropuncture kits, and implantable ports for vascular access [S1].
• Ports include SmartPort, BioFlo Port with Endexo Technology to resist thrombus accumulation, and Xcela Plus Power-Injectable ports [S1].
• The VenaCure EVLT laser system treats superficial venous disease using laser energy with advanced fiber technology for patient comfort and procedural efficiency [S1].
• Solero Microwave Tissue Ablation System is indicated for ablation of soft tissue masses in open, laparoscopic, and percutaneous procedures [S1].
• Sales are primarily direct in the US and through distributors internationally, targeting interventional radiologists, cardiologists, vascular surgeons, urologists, oncologists, and critical care nurses [S1,S2].
• The company faces competition from large diversified medical device companies and smaller specialized manufacturers; competes on quality, clinical outcomes, ease of use, reliability, physician familiarity, and cost-effectiveness [S1].
• Recent financial snapshot as of May 31, 2026: cash and equivalents $53.9M, current assets $163.4M, current liabilities $74.7M, current ratio 2.19, cash ratio 0.91 [S1].
• Fiscal year 2026 net loss was $36.7M with basic and diluted EPS of -$0.88 [S1].
• For the nine months ended February 28, 2026, net sales increased 10% to $233.6M, driven by 19.1% growth in Med Tech and 3.2% growth in Med Device segments [S2].
• Gross margin for the nine months ended February 28, 2026 was 54.9%, with Med Tech at 63.3% and Med Device at 47.6% [S2].
• Net loss for the nine months ended February 28, 2026 was $25.3M, or diluted loss per share of $0.61, compared to a loss of $27.9M in the prior year period [S2].
• Recent quarterly results show revenue growth in Med Tech products including Auryon, thrombus management platform, and NanoKnife, with some softness in Ports and Oncology products in Med Device [S2].
• The company has a backlog of $0.3M as of February 28, 2026 [S2].
• Liquidity is supported by cash on hand and operating cash flows, with no outstanding debt as of May 31, 2026 [S1,S2].
• Recent news highlights include Q4 loss with revenue growth, FDA IDE approval for NanoKnife BPH feasibility study, and expansion of NanoKnife in Europe for multi-organ tumor ablation [N1,N2].